CIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLIC ACID
- $809 - $1943
- Product name: CIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLIC ACID
- CAS: 131779-79-8
- MF: C15H16O5
- MW: 276.28
- EINECS:
- MDL Number:MFCD06201420
- Synonyms:CIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLIC ACID;Cyclohexanecarboxylic acid, 2-(1,3-benzodioxol-5-ylcarbonyl)-, (1R,2S)-rel-
3 prices
Selected condition:
Brand
- Crysdot
- Rieke Metals
Package
- 1g
- 5g
- ManufacturerCrysdot
- Product numberCD11295027
- Product descriptioncis-2-(Benzo[d][1,3]dioxole-5-carbonyl)cyclohexanecarboxylicacid 97%
- Packaging5g
- Price$1857
- Updated2021-12-16
- Buy
- ManufacturerRieke Metals
- Product numberNV00791
- Product descriptionCIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLICACID
- Packaging5g
- Price$1943
- Updated2021-12-16
- Buy
- ManufacturerRieke Metals
- Product numberNV00791
- Product descriptionCIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLICACID
- Packaging1g
- Price$809
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD11295027 | cis-2-(Benzo[d][1,3]dioxole-5-carbonyl)cyclohexanecarboxylicacid 97% | 5g | $1857 | 2021-12-16 | Buy |
Rieke Metals | NV00791 | CIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLICACID | 5g | $1943 | 2021-12-16 | Buy |
Rieke Metals | NV00791 | CIS-2-(3,4-METHYLENEDIOXYBENZOYL)CYCLOHEXANE-1-CARBOXYLICACID | 1g | $809 | 2021-12-16 | Buy |
Properties
Melting point :152-154 °C
Boiling point :494.8±45.0 °C(Predicted)
Density :1.335±0.06 g/cm3(Predicted)
pka :4.48±0.44(Predicted)
Boiling point :494.8±45.0 °C(Predicted)
Density :1.335±0.06 g/cm3(Predicted)
pka :4.48±0.44(Predicted)
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|